Filing Details

Accession Number:
0001209191-16-097454
Form Type:
4
Zero Holdings:
No
Publication Time:
2016-02-10 19:39:31
Reporting Period:
2016-02-08
Filing Date:
2016-02-10
Accepted Time:
2016-02-10 19:39:31
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1571498 Epizyme Inc. EPZM Pharmaceutical Preparations (2834) 261349956
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1632720 E. Andrew Singer C/O Epizyme, Inc.
400 Technology Square
Cambridge MA 02139
Evp & Cfo No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock, Par Value $0.0001 Acquisiton 2016-02-09 20,183 $0.00 20,183 No 4 M Direct
Common Stock, Par Value $0.0001 Acquisiton 2016-02-09 9,329 $0.00 29,512 No 4 M Direct
Common Stock, Par Value $0.0001 Disposition 2016-02-10 12,158 $9.54 17,354 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Acquisiton 2016-02-08 76,400 $0.00 76,400 $8.98
Common Stock Restricted Stock Unit Acquisiton 2016-02-09 80,732 $0.00 80,732 $0.00
Common Stock Restricted Stock Units Disposition 2016-02-09 20,183 $0.00 20,183 $0.00
Common Stock Restricted Stock Units Disposition 2016-02-09 9,329 $0.00 9,329 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
76,400 2026-02-08 No 4 A Direct
80,732 No 4 A Direct
60,549 No 4 M Direct
27,984 No 4 M Direct
Footnotes
  1. Each restricted stock unit represents the contingent right to receive one share of Epizyme, Inc. common stock upon vesting.
  2. The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person to cover taxes associated with the vesting of his restricted stock units.
  3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.99 per share to $9.95 per share, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
  4. This option was granted on February 8, 2016 pursuant to the Company's 2013 Stock Incentive Plan with respect to 76,400 shares of Common Stock, with 25% vesting on February 8, 2017 and the remaining 75% vesting in 36 substantially equal monthly installments thereafter.
  5. This award, granted on February 9, 2016, pursuant to the Company's 2013 Stock Incentive plan, vests as to 25% of the total award on February 9, 2016, with the remaining 75% vesting in 36 substantially equal monthly installments thereafter. Vested shares will be delivered to the reporting person.
  6. This award, granted on February 9, 2015, pursuant to the Company's 2013 Stock Inventive Plan, vests as to 25% of the total award on February 9, 2016, with the remaining 75% vesting in 36 substantially equal monthly installments thereafter. Vested shares will be delivered to the reporting person.